MARKET

JNJ

JNJ

Johnson & Johnson
NYSE
144.47
+2.41
+1.70%
After Hours: 144.25 -0.22 -0.15% 19:57 01/13 EST
OPEN
142.98
PREV CLOSE
142.06
HIGH
145.07
LOW
142.31
VOLUME
10.38M
TURNOVER
--
52 WEEK HIGH
167.51
52 WEEK LOW
139.79
MARKET CAP
347.83B
P/E (TTM)
23.88
1D
5D
1M
3M
1Y
5Y
1D
Cautious Optimism: Evaluating Johnson & Johnson’s Hold Rating Amid ITCI Acquisition Uncertainties
TipRanks · 19h ago
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
Seeking Alpha · 21h ago
BofA moves to No Rating on Intra-Cellular after Johnson & Johnson deal
TipRanks · 1d ago
J&J to acquire Intra-Cellular, Clearwater to buy Enfusion: Morning Buzz
TipRanks · 1d ago
The top and bottom contributors to S&P 500’s Q4 EPS growth
Seeking Alpha · 1d ago
Johnson & Johnson To Present At J.P. Morgan Healthcare Conference; Webcast At 12:00 PM ET
NASDAQ · 1d ago
Johnson & Johnson Bets Big on Mental Health Drugs With $14.6 Billion Intra-Cellular Deal
Barron‘s · 1d ago
What Johnson & Johnson Is Getting With The Acquisition Of Intra-Cellular Therapies
Seeking Alpha · 1d ago
More
About JNJ
Johnson & Johnson, through its subsidiaries, is engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company's primary focus is products related to human health and well-being. It operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, interventional solutions, cardiovascular intervention, and vision fields. The MedTech segment also offers a commercially available intravascular lithotripsy (IVL) platform for coronary artery disease (CAD) and peripheral artery disease (PAD).

Webull offers Johnson & Johnson stock information, including NYSE: JNJ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JNJ stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JNJ stock methods without spending real money on the virtual paper trading platform.